Clinical differences among angiotensin II receptor antagonists

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Six major classes of antihypertensive agents exist, varying in tolerability despite similar efficacy.
• The World Health Organization-International Society of Hypertension (WHO-ISH) endorses all six classes, including Angiotensin II Receptor Antagonists (AIIRAs), for hypertension management.
• Ideal antihypertensives should be effective, well-tolerated, and synergistic with other agents.

Purpose of the Study:

• To compare the antihypertensive efficacy of different Angiotensin II Receptor Antagonists (AIIRAs).
• To investigate potential intra-class differences in efficacy among AIIRAs.
• To assess the clinical implications of varying AIIRA efficacy for agent selection.

Main Methods:

• Review of clinical trials evaluating Angiotensin II Receptor Antagonists (AIIRAs) as monotherapy and in combination.
• Analysis of head-to-head comparisons between losartan and newer AIIRAs.
• Specific clinical trial comparing the blood pressure-reducing effects of irbesartan and valsartan.

Main Results:

• Angiotensin II Receptor Antagonists (AIIRAs) show efficacy comparable to other antihypertensive classes in monotherapy.
• AIIRAs, particularly when combined with hydrochlorothiazide (HCTZ), demonstrate enhanced efficacy.
• Irbesartan achieved statistically superior blood pressure reduction compared to valsartan in a recent clinical trial.

Conclusions:

• While generally well-tolerated, significant differences in antihypertensive efficacy exist among Angiotensin II Receptor Antagonists (AIIRAs).
• Losartan may exhibit weaker antihypertensive effects compared to other AIIRAs.
• The superior efficacy of irbesartan over valsartan has clinical implications for selecting AIIRAs in hypertension treatment.